Wells Fargo’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wells Fargo’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-100,000	Closed	-$83K	–	7040
2020 Q2	$83K	Buy	+100,000	New	+$2.02M	﹤0.01%	5312
2019 Q1	–	Sell	-25,300	Closed	-$38K	–	6540
2018 Q4	$38K	Buy	+25,300	New	+$408K	﹤0.01%	5607

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wells Fargo's ITCI Position: Q2 2025 in Review

Wells Fargo sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,772 shares — an estimated $761K sold.

Wells Fargo first reported a position in ITCI in Q2 2014 and held it in 44 quarters. The position peaked at $4.83M in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Wells Fargo reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Wells Fargo sold 5,772 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $761K.
Wells Fargo first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 44 quarters.
Wells Fargo's Intra-Cellular Therapies Inc. position peaked at $4.83M in Q1 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.